- Home
- EDRY vs OVID Comparison
EDRY vs OVID Comparison
Compare EDRY & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- OVID
- Stock Information
- Founded
- EDRY 2018
- OVID 2014
- Country
- EDRY Greece
- OVID United States
- Employees
- EDRY N/A
- OVID N/A
- Industry
- EDRY Marine Transportation
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- OVID Health Care
- Exchange
- EDRY Nasdaq
- OVID Nasdaq
- Market Cap
- EDRY 25.2M
- OVID 20.6M
- IPO Year
- EDRY N/A
- OVID 2017
- Fundamental
- Price
- EDRY N/A
- OVID $0.34
- Analyst Decision
- EDRY
- OVID Strong Buy
- Analyst Count
- EDRY 0
- OVID 4
- Target Price
- EDRY N/A
- OVID $3.13
- AVG Volume (30 Days)
- EDRY 7.8K
- OVID 1.7M
- Earning Date
- EDRY 08-07-2025
- OVID 08-12-2025
- Dividend Yield
- EDRY N/A
- OVID N/A
- EPS Growth
- EDRY N/A
- OVID N/A
- EPS
- EDRY N/A
- OVID N/A
- Revenue
- EDRY $55,867,583.00
- OVID $548,000.00
- Revenue This Year
- EDRY N/A
- OVID N/A
- Revenue Next Year
- EDRY $28.27
- OVID $5.32
- P/E Ratio
- EDRY N/A
- OVID N/A
- Revenue Growth
- EDRY 10.25
- OVID 15.61
- 52 Week Low
- EDRY $7.60
- OVID $0.24
- 52 Week High
- EDRY $24.73
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- EDRY 60.04
- OVID 56.76
- Support Level
- EDRY $9.15
- OVID $0.30
- Resistance Level
- EDRY $11.85
- OVID $0.33
- Average True Range (ATR)
- EDRY 0.58
- OVID 0.03
- MACD
- EDRY 0.09
- OVID 0.00
- Stochastic Oscillator
- EDRY 33.83
- OVID 85.13
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.